This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Yuri (Jurijus) Gleba
CEO at Nomad Bioscience GmbH


Dr. Gleba has over 30 years of research and management experience in plant genetics and biotechnology. (M. Sc., Kiev University, 1971; Ph.D., Institute of Botany, Academy of Sciences of Ukraine, 1974; Prof., D.Sc., Leningrad University, 1980).

Dr. Gleba’s pioneering research in plant genetics, physiology and biotechnology was published in more than 220 research papers, books and over 50 patent families, and has earned respect of the international scientific community as evidenced by his election to the World Academy of Arts and Science, the European Academy (Academia Europaea), the National German Academy Leopoldina, the National Ukrainian Academy of Sciences, the Lithuanian Academy of Science and the Bavarian Academy of Sciences. In recognition of his outstanding scientific contributions, he also received numerous international and national awards and prizes, including Koerber Prize (Hamburg), A. von Humboldt Prize (Bonn), USSR State Prize (Moscow), State Prize of Ukraine (Kiev), etc.

He founded the Institute of Cell Biology and Genetic Engineering, Ukrainian Academy of Sciences, Kiev, Ukraine, in 1989, and was serving as its Director until 2010.

Dr. Gleba left former USSR in 1991 and joined American Cyanamid Company, Princeton, NJ, where he developed research efforts in plant biotechnology and genomics and crop engineering as a Director of Crop Engineering Department. Dr. Gleba left American Cyanamid/American Home Products in 1999 and founded Icon Genetics, Princeton/Munich/Halle, a plant biotechnology company group; he has been serving since its inception until 2015 as its CEO. Under his leadership, Icon has developed multiple plant expression technologies, including the magnICON® transient technology that has been brought to a commercial level and cGMP compliance and has been used to support clinical trials of the product candidates developed by Icon/Bayer and by Mapp Pharmaceutical. Icon has created one of the best IP portfolios in plant biotechnology that currently includes over 450 issued patents representing 42 patent families of patents/applications. He also founded/cofounded four other companies, including Nomad Bioscience GmbH, Germany, Nambawan Biotech GmbH, Germany and Nomads UAB, Lithuania. In January 2012, Dr. Gleba engineered the acquisition of Icon Genetics from Bayer by Nomad Bioscience, and in August 2015, the sale of Icon Genetics to Denka, Japan. Currently, he is CEO of nomad Bioscience, Munich, Germany. During 2016-21, Nomad has received nine GRAS registrations for its food additives in USA.

Agenda Sessions

  • In high demand, but highly demanding. Current challenges in the development of anti-infectives